Viral shedding seen in plasma donors who have recovered from COVID-19

Researchers from the University of Wisconsin-Madison have found that plasma donors who have recovered from the deadly COVID-19 infection were still shedding viral RNA. This could be significant they write in their article titled, “Prolonged viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors,” that is published on the preprint server Medrxiv* prior to the peer-review process.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

What was the study about?

The COVID-19 pandemic has gripped the world with millions affected and hundreds of thousands killed. The virus causing this infection, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can be life-threatening. As the virus is new, there are no proven therapies against infection. Plasma from those who have recovered from the infection is being collected and used experimentally in various countries. This plasma is said to contain antibodies against the virus, which could help patients fight the infection.

Shedding of the virus is another problem, especially among those who have recovered from the infection, explain the researchers. They write that the medical community is aware of the modes of spread of the virus from one person to another. Still, it is not clear, the duration of such viral shedding after recovery from the symptoms of the infection. This study was undertaken to “determine how long the SARS-CoV-2 remains detectable following self-reporting of viral symptom resolution.”

The team wrote that traditionally on recovery from the symptoms, a period of quarantine for two weeks is recommended for the convalescent patients to prevent the spread of the infection from them to others. The validity of claims that the patient does not shed the virus particles after this period is still not known, explain the researchers.

What was done?

For this study, a total of 86 participants were chosen. The researchers wrote, “152 potential participants were screened, of which five declined, 54 were ineligible, and 93 were included. 86 of 93 completed testing.”

These were SARS CoV-2 positive patients previously who had been re-tested and found to be negative. This negative test was proof that these patients had made a complete viral recovery. The samples tested were those from nasal swab and amplification of the nucleic acids found in the viral particles. The negative test was conducted less than 28 days after the patients had reported having complete symptom resolution. The participants were evaluated to be potential plasma donors to active cases of COVID-19.

The study was conducted in a middle-sized city, and participants were tested at a drive-through testing center. All participants underwent “nasopharyngeal sampling and subsequent nucleic acid amplification for SARS-CoV-2 genes” or rtPCR.

What was found?

Results showed that 13 percent of the participants (11 of the 86) were positive between 12 to 24 days (median 19 days) after complete symptoms were resolved. Elderly participants were more likely to remain positive even after the symptoms had resolved, the study showed. The positive test participants were similar to those who tested negative in terms of days since recovery from the symptoms, the researchers wrote.

Conclusions and implications

The team wrote that the duration for how long a patient remains contagious and capable of transmission of SARS-CoV-2 even after symptoms are resolved is not known. They added that those who do not show symptoms also shed the virus particles, as has been seen in previous studies. They wrote, “Previous studies have detected SARS-CoV-2 RNA in respiratory secretions 13-29 days after symptom onset.” They conclude that patient isolation is dependent on the duration of viral shedding, and thus this is significant evidence. This study showed that 13 percent of the patients shed the virus even after symptom resolution, and negative tests and positive patients were significantly older, and these older patients also had a higher viral load during their testing.

This study concluded that COVID-19 convalescent patients who are to be considered for the donation of plasma need to be tested again within 28 days after symptom resolution because they may still be shedding the virus actively. The team wrote that these findings show that patients who have been COVID-19 positive may need a long period of quarantine even after “recovery” from the symptoms to prevent the spread of the infection to healthy persons. This period of extended quarantine should be beyond two weeks, they wrote.

In conclusion, the team wrote, “These data demonstrate that COVID-19 patients continue to shed detectable viral RNA for 2-4 weeks after resolution of symptoms. Efficient testing to confirm resolution of COVID-19 for surveillance and convalescent plasma programs should likely focus on patients outside this window.”

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Mar 20 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, March 20). Viral shedding seen in plasma donors who have recovered from COVID-19. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20200515/Viral-shedding-seen-in-plasma-donors-who-have-recovered-from-COVID-19.aspx.

  • MLA

    Mandal, Ananya. "Viral shedding seen in plasma donors who have recovered from COVID-19". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20200515/Viral-shedding-seen-in-plasma-donors-who-have-recovered-from-COVID-19.aspx>.

  • Chicago

    Mandal, Ananya. "Viral shedding seen in plasma donors who have recovered from COVID-19". News-Medical. https://www.news-medical.net/news/20200515/Viral-shedding-seen-in-plasma-donors-who-have-recovered-from-COVID-19.aspx. (accessed November 22, 2024).

  • Harvard

    Mandal, Ananya. 2023. Viral shedding seen in plasma donors who have recovered from COVID-19. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20200515/Viral-shedding-seen-in-plasma-donors-who-have-recovered-from-COVID-19.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes